More than 440 SCI articles published!  BGI's cancer genetics and cell research fuel innovation

More than 440 SCI articles published! BGI’s cancer genetics and cell research fuel innovation

BGI has currently published over 440 SCI (Science Citation Index) articles in the field of cancer research, with a cumulative impact factor of over 4,000 points. A steady number of important BGI articles have been published in Nature Medicine, Cell, Nature, Science, Cell Research, Nature Genetics and other leading scientific journals, including over 40 papers with scores above 30 and nearly 70 papers with scores above 10.

BGI’s research scope covers more than 20 types of cancers, including lung cancer, esophageal cancer, colorectal cancer, gastric cancer, pancreatic cancer, liver cancer, breast cancer , cervical cancer, endometrial cancer, nasopharyngeal cancer, thyroid cancer, prostate cancer, lymphoma, melanoma, glioma and brain tumor. As we have a lot of material to cover, we will present these scientific results published by BGI in batches. Today, we take a quick look at six high-impact searches.

Panoramic immune profiling of early recurrent hepatocellular carcinoma using single cell technology

Release date: January 21, 2021

Publication: Cell IF 66.850

Research Results: Hepatocellular carcinoma (HCC) has a high recurrence rate and a low 5-year survival rate. The team used single-cell sequencing to analyze transcriptome information from approximately 17,000 cells from 18 cases of primary or early recurrent HCC. Grouped into two distinct cohorts, early recurrent tumors showed reduced levels of regulatory T cells, increased levels of dendritic cells (DCs) and infiltrating CD8+ T cells, compared to primary tumors. Notably, CD8+ T cells differed from the classic depleted state seen in primary HCC and were instead characterized by high expression of KLRB1 (CD161) in an innate-like, low kill, low clonal expansion state. The increase in these cells was associated with a poorer prognosis of HCC. The team also revealed a potential mechanism of immune evasion in recurrent tumor cells that inhibits DC antigen presentation and recruits innate CD8+ T cells, thereby providing a better understanding and more reliable basis for a comprehensive understanding of immune evasion mechanisms associated with tumor recurrence in the HCC ecosystem. .

Full article link

Comprehensive gene expression profiling identifies potential pathways of endothelial cell heterogeneity and angiogenesis in lung tumors

Posted: January 13, 2020

Publication: Cancer cell IF 38.585

Research Results: At the single cell level, there are few studies on the heterogeneity of lung tumor endothelial cell (ETC) phenotypes across patients, species (human/mouse) and models (in vivo /in vitro). The team sequenced single-cell RNA (scRNA) from 56,771 human/mouse lung tumor endothelial cells and cultured human lung TECs, identified 17 known and 16 previously unknown phenotypes, including TECs regulating the function of immune monitoring. We resolved the canonical spike TECs into a known migratory spike and the other category with a basement membrane plasticity breakthrough phenotype (spike/gap TEC). Of these 2, the TEC spike expression profile is correlated with patient survival, while the TEC spike/gap phenotype is the most sensitive to vascular endothelial growth factor inhibitors. Among the different TEC phenotypes, only the TEC tip has cross-species, cross-pattern consistency and co-expresses conserved marker genes. After integrating and analyzing single-cell transcriptome sequencing data, independent bulk multi-omics data, and meta-analysis data from different human tumors and validating them with functional analysis, the researchers identified collagen modification as a new candidate angiogenic pathway.

Link to full article

Genome-wide profiling of HPV integration in cervical cancer identifies oncogenic hotspots and potential mechanisms of oncogenesis

Posted: January 12, 2015

Impact Factor: Nature Genetics IF 41.307

Research Results: Cervical cancer is the most common malignancy of the female reproductive tract, and human papillomavirus (HPV) integration is a key event in cervical carcinogenesis. By performing genome-wide HPV integration profiling in cervical cancer (CC), the team identified clusters of genomic loci and revealed a potential mechanism for HPV-mediated integration. microhomology. In more than 100 samples, 3667 HPV integration loci were identified, in addition to some common integration loci: POU5F1B (9.7%), FHIT (8.7%), KLF12 (7.8%) , KLF5 (6.8%), LRP1B (5.8%) and LEPREL1 (4.9%). A few new loci were also identified: HMGA2 (7.8%), DLG2 (4.9%) and SEMA3D (4.9%). These identified integration loci can be used as biomarkers for early personalized treatment and prognostic assessment of CC. Moreover, the expression of FHIT and LRP1B proteins was downregulated when HPV was integrated into the FHIT and LRP1B introns, while the expression of MYC and HMGA2 proteins was elevated when HPV was integrated into the flanking regions. Moreover, the microhomology sequence between the human and HPV genomes was found to be significantly enriched near the integration site, suggesting that fusion between viral and human DNA may occur through a repair pathway of the DNA mediated microhomology.

Link to full article

Molecular typing of gastric cancer can be used to identify different prognostic outcomes for patients

Posted: April 20, 2015

Publication: Nature Medicine IF 87.241

Research results: Gastric cancer (GC) is one of the deadliest cancers and it is very heterogeneous. The research team combined GC heterogeneity characteristics and gene expression data to establish four molecular subtypes associated with different patterns of molecular alterations, disease progression and prognosis: MSI subtype ( microsatellite instability), MSI/EMT (microsatellite instability/epithelial-mesenchymal transition) subtype, MSS (microsatellite stability)/TP53+ subtype and MSS/TP53- subtype, which can help develop more personalized treatment plans for different patients. MSI/EMT subtypes can help develop more rational and personalized treatment plans for different patients. Among them, MSI/EMT has the worst prognosis, tends to occur in young patients, and has the highest relapse frequency (63%) among the four subtypes. The MSI subtype is common in the sinuses and pylorus (70%) and often has an intestinal subtype (60%), with the best overall prognosis and lowest relapse frequency (22%). The MSS (stable microsatellite)/TP53+ subtype and the MSS/TP53- subtype both have intermediate prognosis and relapse rates. In addition, EBV virus infection rates were higher in the MSS/TP53+ subtype than in the other three groups.

Link to full article

FGFR-TACC gene fusion transformation induces malignant glioblastoma

Posted: September 7, 2012

Publication: Science IF 63.714

Research Results: Glioblastoma multiforme (GBM), a brain tumor, is one of the deadliest cancers in humans. The team found that a small proportion of GBMs (3.1%; 3 of 97 tumors examined) contain oncogenic chromosomal translocations that allow the tyrosine kinase coding domains (FGFR1 or FGFR3) of the factor receptor gene growing fibroblasts (FGFR) to fuse with TACC1 or TACC3, respectively, which encode the structural domain of the translesional acidic convoluted helix (TACC). The FGFR-TACC fusion protein exhibits oncogenic activity when introduced into astrocytes or stereotactically transduced into mouse brain. At the same time, it has constitutive kinase activity when localized to both poles of the mitotic spindle, inducing mitotic and chromosomal segregation defects, thereby triggering aneuploidy. Inhibition of FGFR kinase activity corrects aneuploidy, so oral FGFR inhibitors prolong the survival time of FGFR3-TACC3-induced intracranial glioma mice. FGFR-TACC fusion should be a potential predictor of whether some patients with GBM will benefit from treatment with targeted FGFR kinase inhibitors.

Link to full article

Genomic basis and genetic mechanisms of transcriptomic changes in pancancer species

Posted: February 5, 2020

Publication: Nature SI 69.5

Research results: Transcriptional alterations are usually caused by somatic changes in the cancer genome. During cancer development, several modes of RNA alteration are covered, such as overexpression, altered splicing, and gene fusion. However, correlating them with underlying genomic changes is difficult due to heterogeneity between patients and tumor types. The team used paired whole genome sequencing data to correlate multiple RNA alterations with germline and somatic DNA alterations to come up with a catalog of genetic alterations associated with cancer in 27 different cancer types. . The study identified 1,900 splicing alterations associated with somatic mutations; it also confirmed that 82% of gene fusions were associated with structural variants. Moreover, transcriptomic alterations were accompanied by different characterizations in each cancer, but were all associated with changes in DNA mutational characteristics. This study of RNA alterations in a genomic context provides a solid foundation for uncovering genes and genetic mechanisms associated with cancer function.

Link to full article

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world’s leading provider of integrated precision medicine solutions. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange. the 2022 Nature Index annual tables.

#SCI #articles #published #BGIs #cancer #genetics #cell #research #fuel #innovation

Leave a Comment

Your email address will not be published. Required fields are marked *